September 15th 2025
Most parents support childhood vaccines like MMR and polio, but skepticism about seasonal and newer shots persists along with distrust of federal agencies.
FDA Approves GSK Vaccine Arexvy for Prevention of RSV in High-Risk Adults Aged 50 to 59 Years
June 7th 2024GSK announced today approval by the US FDA of a label expansion for the adjuvanted RSV vaccine that adds adults aged 50 to 59 years who are at elevated risk for RSV disease to the vaccine’s current indication.